To include your compound in the COVID-19 Resource Center, submit it here.

Apic: Dual-gene therapies

How Apic is developing a dual function gene therapy for AAT deficiency

Apic Bio Inc.'s APB-101 is a dual-function gene therapy for AAT deficiency that silences the mutant AAT gene and augments wild-type AAT expression, which the company believes gives it greater efficacy and lower liver toxicity than other gene silencing or gene replacement therapies for the disease.

Apic's John Reilly and Christian Mueller said APB-101, which was designed using Apic's THRIVE platform, differs

Read the full 613 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE